Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort B of the phase 1b/2 KEYNOTE-365 study.

被引：0
|
作者：
Massard, Christophe
Retz, Margitta
Hammerer, Peter
Quevedo, Fernando
Fong, Peter C. C.
Berry, William R.
Gurney, Howard
Piulats, Josep M.
Joshua, Anthony M.
Linch, Mark David
Kolinsky, Michael Paul
Romano, Emanuela
Sridhar, Srikala S.
Conter, Henry Jacob
Augustin, Marinela
Wu, Helen
Schloss, Charles
Poehlein, Christian Heinrich
Yu, Evan Y.
机构：
[1] Gustave Roussy Canc Campus, Villejuif, France
[2] Univ Paris Sud, Villejuif, France
[3] Tech Univ Munich, Rechts Isar Univ Hosp, Munich, Germany
[4] Acad Hosp Braunschweig, Braunschweig, Germany
[5] Mayo Clin, Rochester, MN USA
[6] Auckland City Hosp, Auckland, New Zealand
[7] Duke Univ, Sch Med, Cary, NC USA
[8] Macquarie Univ Hosp, Sydney, NSW, Australia
[9] Catalan Canc Inst, Barcelona, Spain
[10] St Vincents Hosp, Kinghorn Canc Ctr, Sydney, NSW, Australia
[11] UCL, Inst Canc, London, England
[12] Cross Canc Inst, Edmonton, AB, Canada
[13] Inst Curie, Paris, France
[14] Princess Margaret Canc Ctr, Toronto, ON, Canada
[15] Univ Western Ontario, Brampton, ON, Canada
[16] Klinikum Nurnberg, Nurnberg, Germany
[17] Merck & Co Inc, Kenilworth, NJ USA
[18] Univ Washington, Seattle, WA 98195 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.5029
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5029
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Keynote-365 cohort b: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).
    Massard, Christophe
    Retz, Margitta
    Hammerer, Peter
    Quevedo, Fernando
    Fong, Peter C. C.
    Berry, William R.
    Gurney, Howard
    Piulats, Josep M.
    Joshua, Anthony
    Linch, Mark David
    Kolinsky, Michael
    Romano, Emanuela
    Sridhar, Srikala S.
    Conter, Henry Jacob
    Augustin, Marinela
    Wu, Haiyan
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [2] Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort C of the phase 1b/2 KEYNOTE-365 study.
    Fong, Peter C. C.
    Retz, Margitta
    Drakaki, Alexandra
    Massard, Christophe
    Berry, William R.
    Romano, Emanuela
    De Bono, Johann S.
    Feyerabend, Susan
    Appleman, Leonard Joseph
    Conter, Henry Jacob
    Sridhar, Srikala S.
    Shore, Neal D.
    Linch, Mark David
    Joshua, Anthony M.
    Gurney, Howard
    Wu, Helen
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
    Kolinsky, Michael Paul
    Gravis, Gwenaelle
    Mourey, Loic
    Piulats, Josep M.
    Sridhar, Srikala S.
    Romano, Emanuela
    Berry, William R.
    Gurney, Howard
    Retz, Margitta
    Appleman, Leonard Joseph
    Boegemann, Martin
    De Bono, Johann S.
    Joshua, Anthony M.
    Emmenegger, Urban
    Conter, Henry Jacob
    Laguerre, Brigitte
    Wu, Helen
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [4] Keynote-365 cohort C: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).
    Fong, Peter C. C.
    Retz, Margitta
    Drakaki, Alexandra
    Massard, Christophe
    Berry, William R.
    Romano, Emanuela
    De Bono, Johann S.
    Feyerabend, Susan
    Appleman, Leonard Joseph
    Conter, Henry Jacob
    Sridhar, Srikala S.
    Shore, Neal D.
    Linch, Mark David
    Joshua, Anthony
    Gurney, Howard
    Wu, Haiyan
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [5] Pembrolizumab (pembro) plus docetaxel and prednisone in patients with abiraterone acetate (abi)- or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B update
    Romano, E.
    Sridhar, S. S.
    Kolinsky, M. P.
    Gravis, G.
    Mourey, L.
    Piulats, J. M.
    Berry, W. R.
    Gurney, H.
    Retz, M.
    Appleman, L. J.
    Boegemann, M.
    de Bono, J. S.
    Joshua, A. M.
    Emmenegger, U.
    Conter, H. J.
    Laguerre, B.
    Wu, H.
    Qiu, P.
    Schloss, C.
    Yu, E. Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S512 - S513
  • [6] KEYNOTE-365 cohort C updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
    Berry, William R.
    Fong, Peter C. C.
    Piulats, Josep M.
    Appleman, Leonard Joseph
    Conter, Henry Jacob
    Feyerabend, Susan
    Shore, Neal D.
    Gravis, Gwenaelle
    Laguerre, Brigitte
    Gurney, Howard
    Retz, Margitta
    Romano, Emanuela
    Mourey, Loic
    De Bono, Johann S.
    Kam, Audrey E.
    Emmenegger, Urban
    Wu, Helen
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [7] Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort A of the phase 1b/2 KEYNOTE-365 study.
    Yu, Evan Y.
    Massard, Christophe
    Retz, Margitta
    Tafreshi, Ali
    Carles, Joan
    Hammerer, Peter
    Fong, Peter C. C.
    Shore, Neal D.
    Joshua, Anthony M.
    Linch, Mark David
    Gurney, Howard
    Romano, Emanuela
    Augustin, Marinela
    Piulats, Josep M.
    Wu, Helen
    Schloss, Charles
    Poehlein, Christian Heinrich
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Pembrolizumab (pembro) plus docetaxel and prednisone in patients (pts) with abiraterone acetate (abi) or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B efficacy, safety and, biomarker results.
    Sridhar, Srikala S.
    Kolinsky, Michael Paul
    Gravis, Gwenaelle
    Mourey, Loic
    Rodriguez, Jose Maria M. Piulats
    Romano, Emanuela
    Berry, William R.
    Gurney, Howard
    Retz, Margitta
    Appleman, Leonard Joseph
    Boegemann, Martin
    De Bono, Johann S.
    Joshua, Anthony M.
    Emmenegger, Urban
    Conter, Henry Jacob
    Laguerre, Brigitte
    Wu, Haiyan
    Qiu, Ping
    Schloss, Charles
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Pembrolizumab (pembro) plus enzalutamide (enza) in patients with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort C update
    Mourey, L.
    Conter, H. J.
    Shore, N.
    Berry, W. R.
    Fong, P. C.
    Piulats, J. M.
    Appleman, L. J.
    Todenhoefer, T.
    Gravis, G.
    Laguerre, B.
    Gurney, H.
    Retz, M.
    Romano, E.
    de Bono, J. S.
    Kam, A. E.
    Emmenegger, U.
    Wu, H.
    Qiu, P.
    Schloss, C.
    Yu, E. Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S516 - S517
  • [10] KEYNOTE-921: Phase III study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Petrylak, D. P.
    Li, B.
    Schloss, C.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2019, 30 : 351 - 351
12345